Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
For Physicians
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
We focus on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
Phase Two
Current
Projected
Drug/Study Design
Pre-Clinical
Phase 1
Phase 2
Phase 3
Custirsen
Prostate Cancer
Combination with 1st Line Chemo (SYNERGY)
Combination with 2nd Line Chemo (AFFINITY)
Non-Small Cell Lung Cancer
Combination with Chemotherapy (ENSPIRIT)
OGX-427
Prostate Cancer
Combination with prednisone (pre-chemo)
Combination with Zytiga pre or post-chemo (Pacific)
Bladder Cancer
Superficial/muscle-invasive
Combination with 1st Line Chemo (metastatic)(Borealis-1)
Combination with 2nd Line Chemo (metastatic)(Borealis-2)
Lung Cancer
Combination with 1st Line Chemo (Spruce)
Pancreatic Cancer
Combination with 1st line Chemo (metastatic) (Rainier)
OGX-225
Solid Tumors
